BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming December 15, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Baxter International, Inc. ("Baxter†or the "Company†) (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025, inclusive (the "Class Period†). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BAXTER INTERNATIONAL, INC. (BAX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTI. ...

Core Viewpoint - Baxter International, Inc. is facing a federal securities class action lawsuit due to safety concerns regarding its Novum IQ Large Volume Pump, which has been linked to serious patient injuries and deaths, leading to a significant decline in the company's stock price [4][5]. Summary by Sections Incident Overview - On April 7, 2025, safety issues regarding Baxter's Novum IQ Large Volume Pump emerged after a whistleblower reported inaccuracies in infusion [4]. - Baxter issued warning letters on April 24 and July 14, 2025, acknowledging risks of underinfusion and overinfusion, with reports of 79 serious injuries and two patient deaths [4]. - Following the announcement of a temporary pause in shipments on July 31, 2025, Baxter's stock price fell by $6.29, approximately 22.4%, from $28.05 to $21.76 [4]. Lawsuit Details - The lawsuit is on behalf of investors who purchased Baxter securities from February 23, 2022, to July 30, 2025 [5]. - Allegations include failure to disclose systemic defects in the Novum LVP, inadequate responses to reported malfunctions, and the heightened risk of halting new sales of the pumps [5].

Oct 28, 2025 12:06 PM Eastern Daylight Time Law Offices of Frank R. Cruz Encourages Baxter International, Inc. (BAX) Shareholders to Inquire About Securities Fraud Class Action Share LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased Baxter International, Inc. ("Baxter†or the "Company†) (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025, inclusive (the "Class Period†). Baxter invest ...

Key Takeaways BAX's Q3 revenues are estimated at $2.87B, up 6.4% year over year, with EPS projected at 60 cents.Advanced Surgery, Compounding, and Care & Connectivity likely drove BAX's operational growth.IV fluid conservation, anesthesia weakness, and paused pump shipments may have limited BAX's margins.Baxter International Inc. (BAX) is scheduled to release third-quarter 2025 results on Oct. 30, before the opening bell. In the last reported quarter, the company’s earnings missed the Zacks Consensus Estima ...

Accessibility StatementSkip Navigation NEW YORK, Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Baxter International, Inc. ("Baxter" or the "Company") (NYSE: BAX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concer ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International Inc. due to allegations of false and misleading statements regarding the safety and efficacy of its Novum LVP product, which has led to significant investor losses [1][3]. Summary by Relevant Sections Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Baxter between February 23, 2022, and July 30, 2025, to discuss their legal rights [1]. - The firm has set a deadline of December 15, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Baxter [1]. Allegations Against Baxter - The complaint alleges that Baxter and its executives violated federal securities laws by failing to disclose systemic defects in the Novum LVP, which caused malfunctions and posed risks to patients [3]. - Specific issues included underinfusion, overinfusion, and complete non-delivery of fluids, which led to serious injuries and deaths [3]. - Baxter's attempts to address these defects were deemed inadequate, and the company faced a heightened risk of halting sales of the Novum LVP [3]. Impact on Stock Performance - The extent of the alleged fraud was revealed on July 31, 2025, when Baxter announced a voluntary pause in shipments and installations of the Novum LVP, resulting in a 22.4% drop in stock price, closing at $21.76 [4]. Class Action Participation - The lead plaintiff in a class action is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [5]. - Members of the putative class can choose to serve as lead plaintiff or remain absent, with their ability to recover not affected by this decision [5]. Additional Information - Faruqi & Faruqi encourages anyone with information regarding Baxter's conduct, including whistleblowers and former employees, to contact the firm [5].

Accessibility StatementSkip Navigation NEW YORK, Oct. 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Baxter International, Inc. ("Baxter International, Inc." or the "Company") (NYSE: BAX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Baxter International, Inc. investors who were adversely affected by alleged securities fraud between February 23, 2022 and July 30, 2025. Follow the link below to get more information and be contac ...

NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Baxter International Inc. (NYSE: BAX) and certain of the Company’s senior executives for securities fraud after significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Baxter, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/baxter-international-inc ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought Baxter common stock between February 23, 2022, and July 30, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 15, 2025 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [4]. - The firm has been recognized for its achievements, including being ranked No. 1 for securities class action settlements in 2017 and securing over $438 million for investors in 2019 [4]. Group 3: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients [5]. - Specific claims include that Baxter was aware of multiple malfunctions and injuries related to the device but did not take adequate remedial measures, resulting in misleading statements about the product's safety and efficacy [5].

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Baxter International, Inc. (NYSE:BAX), Spirit Aviation Holdings, Inc. (OTCMKTS:FLYYQ), and Molina Healthcare, Inc. (NYSE: MOH). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Baxt ...